Pot for thought? How about a better explanation of the science before we send HIV patients to the green pharmacy.
Whether this particular treatment revolutionizes the landscape for hemophilia B sufferers will remain an open question for some years–and the story should have emphasized that more.
Readers aren’t even told if the procedure will be available in the US.
The more recent release does a better job of addressing benefits and the quality of the evidence.
To its credit, the story competently describes the study methods and findings.
However, the headline’s a bit more positive than perhaps it should be, and information about financial costs and potential harms is missing,
But, the piece does a good job putting the results into context and even compares those findings to the placebo group, giving them a more transparent and helpful context.